T cells co-producing Mycobacterium tuberculosis-specific type 1 cytokines for the diagnosis of latent tuberculosis

European Cytokine Network

Volumn 21, Issue 1, 2010, Pages 34-39

  Nemeth, Johannes ^a,c   Winkler, Heide Maria ^a   Karlhofer, Franz ^b   Selenko Gebauer, Nicole ^b   Graninger, Wolfgang ^a   Winkler, Stefan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anti TNF treatment; Diagnosis; IFN ; Latent tuberculosis; Mycobacterium tuberculosis; TNF

Indexed keywords

EARLY SECRETION ANTIGENIC TARGET 6; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PSORIASIS; SKIN DISEASE; T LYMPHOCYTE; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; LATENT TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ROC CURVE; SPECIES SPECIFICITY; TUBERCULIN; TUBERCULIN TEST; YOUNG ADULT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 77149132476     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0182     Document Type: Article

References (23)

1. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-5.
2. Kaufmann SH. Tuberculosis: back on the immunologists' agenda. Immunity 2006; 24: 351-7.
3. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factoralpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 6: 561-72.
4. Food and Drug Administration. Safety update on TNF-α Antagonists. www.fda.gov. Last assessed 17.9.2009.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
6. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Inf Dis 2002; 34: 365-70.
7. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003; 62: 1241-2.
8. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1.
9. Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996; 64: 16-22.
10. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-84.
11. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147-52.
12. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209-17.
13. EuroTB. http://www.eurotb.org/country-profiles/austria.pdf. Last assessed on the 3.11.2009.
14. Taylor Z, Nolan CM, Blumberg HM, American Thoracic Society. Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54 (RR-12): 1-81 (Erratum in: MMWR Morb Mortal Wkly Rep. 2005; 54: 1161).
15. Nemeth J, Winkler HM, Zwick RH, et al. Recruitment of Mycobacterium tuberculosis specific CD4+ T cells to the site of infection for diagnosis of active tuberculosis. J Intern Med 2009; 265: 163-8.
16. Winkler S, Necek M, Winkler H, et al. Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa. Microbes Infect 2005; 7: 1161-9.
17. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008; 35: 1271-6.
18. Sellam J, Hamdi H, Roy C, et al. RATIO (Research Axed on Tolerance of Biotherapies) Study Group. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 1610-5.
19. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 776-81.
20. Coaccioli S, Di Cato L, Marioli D, et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 2000; 42: 263-6.
21. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-10.
22. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-5.
23. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-204.